apolizumab

BIOLOGICAL6 trials

Sponsors

National Cancer Institute (NCI), PDL BioPharma, Inc., Stanford University

Conditions

Chronic Lymphocytic LeukemiaDiffuse Large B-Cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueFollicular LymphomaLymphomaMantle Cell LymphomaNodal Marginal Zone B-cell LymphomaNoncontiguous Stage II Marginal Zone Lymphoma

Phase 1

Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia

TerminatedNCT00022971

National Cancer Institute (NCI)Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma +2

Start: 2001-08-15End: 2017-03-17Updated: 2019-12-16

Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia

CompletedNCT00017472

National Cancer Institute (NCI)Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma +11

Start: 2001-04-30Target: 35Updated: 2013-06-04

Monoclonal Antibody Therapy in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

CompletedNCT00004101

National Cancer Institute (NCI)Lymphoma

Start: 1999-11-30Updated: 2013-02-11

Phase 2

Monoclonal Antibody Therapy in Treating Patients With Recurrent Hodgkin's Lymphoma

CompletedNCT00055783

Stanford UniversityLymphoma

Start: 2002-07-31End: 2003-04-30Updated: 2013-05-15

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

PDL BioPharma, Inc.Lymphoma

Start: 2000-10-31Updated: 2013-12-18

Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

CompletedNCT00089154

National Cancer Institute (NCI)Noncontiguous Stage II Small Lymphocytic Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia +2

Start: 2004-08-31Updated: 2013-07-16